These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15108253)

  • 1. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
    Yao FY; Bass NM; Ascher NL; Roberts JP
    Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
    Yao FY; Bass NM; Nikolai B; Merriman R; Davern TJ; Kerlan R; Ascher NL; Roberts JP
    Liver Transpl; 2003 Jul; 9(7):684-92. PubMed ID: 12827553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.
    Yao FY; Bass NM; Nikolai B; Davern TJ; Kerlan R; Wu V; Ascher NL; Roberts JP
    Liver Transpl; 2002 Oct; 8(10):873-83. PubMed ID: 12360427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Huang YH; Su CW; Lin HC; Chiang JH; Chiou YY; Huo SC; Lee PC; Lee SD
    Clin Transplant; 2008; 22(4):469-75. PubMed ID: 18318736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.
    Shetty K; Timmins K; Brensinger C; Furth EE; Rattan S; Sun W; Rosen M; Soulen M; Shaked A; Reddy KR; Olthoff KM
    Liver Transpl; 2004 Jul; 10(7):911-8. PubMed ID: 15237377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of liver transplantation for hepatocellular carcinoma among allocation organ policy strategies, neoadjuvant treatments, and intention-to-treat analysis.
    Andorno E; Bottino G; Morelli N; Casaccia M; Gelli M; Piredda D; Immordino G; Ferrante R; Nardi I; Troilo BM; Di Domenico S; Ravazzoni F; Valente U
    Transplant Proc; 2008; 40(6):1972-3. PubMed ID: 18675103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.
    Hayashi PH; Trotter JF; Forman L; Kugelmas M; Steinberg T; Russ P; Wachs M; Bak T; Kam I; Everson GT
    Liver Transpl; 2004 Jan; 10(1):42-8. PubMed ID: 14755776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era.
    Ravaioli M; Grazi GL; Ercolani G; Cescon M; Del Gaudio M; Zanello M; Ballardini G; Varotti G; Vetrone G; Tuci F; Lauro A; Ramacciato G; Pinna AD
    Transplantation; 2006 Feb; 81(4):525-30. PubMed ID: 16495798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
    Ioannou GN; Perkins JD; Carithers RL
    Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus.
    Thuluvath PJ; Maheshwari A; Thuluvath NP; Nguyen GC; Segev DL
    Liver Transpl; 2009 Jul; 15(7):754-62. PubMed ID: 19562709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
    Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
    Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.
    Leung JY; Zhu AX; Gordon FD; Pratt DS; Mithoefer A; Garrigan K; Terella A; Hertl M; Cosimi AB; Chung RT
    Liver Transpl; 2004 Nov; 10(11):1343-54. PubMed ID: 15497158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
    Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
    Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of model for end-stage liver disease on patient survival and disease-free survival in patients receiving liver transplantation for hepatocellular carcinoma.
    Moonka D; Castillo E; Kumer S; Abouljoud M; Divine G; Pelletier S
    Transplant Proc; 2009; 41(1):216-8. PubMed ID: 19249517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation for hepatocellular carcinoma: results of a multicenter study with common priorization criteria.
    Santoyo J; Sanchez B; de la Mata M; Fernández-Aguilar JL; Lopez-Ciller P; Pascasio JM; Suarez MA; Gomez MA; Nogueras F; Muffak K; Cuende N; Alonso M
    Transplant Proc; 2009 Apr; 41(3):1009-11. PubMed ID: 19376412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy.
    Huo TI; Wu JC; Lin HC; Lee FY; Hou MC; Huang YH; Lee PC; Chang FY; Lee SD
    Liver Transpl; 2004 Dec; 10(12):1507-13. PubMed ID: 15558587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.
    Decaens T; Roudot-Thoraval F; Hadni-Bresson S; Meyer C; Gugenheim J; Durand F; Bernard PH; Boillot O; Sulpice L; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Dharancy S; Chazouilleres O; Cherqui D; Duvoux C
    Liver Transpl; 2006 Dec; 12(12):1761-9. PubMed ID: 16964590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.